CPXX continues higher after announcing inferior results to Pracinost + atazacitidine combination therapy.
MEI management feels no compunction to make any press release based on their own superior results. Volume on stock & price looks like MEI has announced closing door as the stock trades below cash with no debt and getting ready to start ME-344 phase 2 cervical and other cancers in the next couple months and phase 3 clinical for highly successful pracinostat + azacitidine for AML a couple months later
It would make sense for CELG to partner with MEI to make their own drug azacitidine (Vidaza) more marketable. Since pracinostat + azacitidine (Vidaza) combination is in MEIP phase 2 and phase 3 that is starting soon. Vidaza by itself is not an answer to AML, but when combined with pracinostat is very successful..